open access

Vol 91, No 12 (2020)
Review paper
Published online: 2020-10-09
Get Citation

Biomarkers of angiogenesis in twin gestations and the risk of preeclampsia — review of the current literature

Szymon Kozlowski, Magdalena Zgliczynska, Katarzyna Kosinska-Kaczynska
DOI: 10.5603/GP.a2020.0133
·
Pubmed: 33447998
·
Ginekol Pol 2020;91(12):773-776.

open access

Vol 91, No 12 (2020)
REVIEW PAPERS Obstetrics
Published online: 2020-10-09

Abstract

Twin pregnancy is one of the key risk factors for the development of preeclampsia.
Soluble fms-like tyrosine kinase-1, placental growth factor, and soluble endoglin are molecules involved in the process of
angiogenesis with a proven role in the pathogenesis of preeclampsia. The aim of the review was to summarize available
data on maternal serum levels of the biomarkers of angiogenesis and their usefulness in predicting preeclampsia in twin
pregnancies. Most of available data suggest biomarkers concentrations differ between singleton and twin gestation and
are related to chorionicity of twin pregnancy. Several algorithms including biomarkers of angiogenesis in prediction of
PE in twin pregnancy are available and seem promising, however more large prospective surveys are necessary to assess
their usefulness in general clinic use.

Abstract

Twin pregnancy is one of the key risk factors for the development of preeclampsia.
Soluble fms-like tyrosine kinase-1, placental growth factor, and soluble endoglin are molecules involved in the process of
angiogenesis with a proven role in the pathogenesis of preeclampsia. The aim of the review was to summarize available
data on maternal serum levels of the biomarkers of angiogenesis and their usefulness in predicting preeclampsia in twin
pregnancies. Most of available data suggest biomarkers concentrations differ between singleton and twin gestation and
are related to chorionicity of twin pregnancy. Several algorithms including biomarkers of angiogenesis in prediction of
PE in twin pregnancy are available and seem promising, however more large prospective surveys are necessary to assess
their usefulness in general clinic use.

Get Citation

Keywords

placental growth factor; serum soluble fms-like tyrosine kinase-1; endoglin; preeclampsia; twin pregnancy

About this article
Title

Biomarkers of angiogenesis in twin gestations and the risk of preeclampsia — review of the current literature

Journal

Ginekologia Polska

Issue

Vol 91, No 12 (2020)

Article type

Review paper

Pages

773-776

Published online

2020-10-09

DOI

10.5603/GP.a2020.0133

Pubmed

33447998

Bibliographic record

Ginekol Pol 2020;91(12):773-776.

Keywords

placental growth factor
serum soluble fms-like tyrosine kinase-1
endoglin
preeclampsia
twin pregnancy

Authors

Szymon Kozlowski
Magdalena Zgliczynska
Katarzyna Kosinska-Kaczynska

References (33)
  1. Abalos E, Cuesta C, Grosso AL, et al. Global and regional estimates of preeclampsia and eclampsia: a systematic review. Eur J Obstet Gynecol Reprod Biol. 2013; 170(1): 1–7.
  2. Prejbisz A, Dobrowolski P, Kosiński P, et al. Postępowanie w nadciśnieniu tętniczym u kobiet w ciąży. Zapobieganie, diagnostyka, leczenie i odległe rokowanie. Stanowisko Polskiego Towarzystwa Nadciśnienia Tętniczego, Polskiego Towarzystwa Kardiologicznego oraz Polskiego Towarzystwa Ginekologów i Położników. Ginekologia i Perinatologia Praktyczna. 2019; 4(2): 43–111.
  3. Williams D, Kenyon A, Adamson D. Physiology. In: Bennett P, Williamson C. ed. Basic Science in Obstetrics and Gynaecology, 4th ed. Churchill Livingstone, London 2010: 173–230.
  4. Phipps EA, Thadhani R, Benzing T, et al. Pre-eclampsia: pathogenesis, novel diagnostics and therapies. Nat Rev Nephrol. 2019; 15(5): 275–289.
  5. Birdir C, Droste L, Fox L, et al. Predictive value of sFlt-1, PlGF, sFlt-1/PlGF ratio and PAPP-A for late-onset preeclampsia and IUGR between 32 and 37 weeks of pregnancy. Pregnancy Hypertens. 2018; 12: 124–128.
  6. Venkatesha S, Toporsian M, Lam C, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med. 2006; 12(6): 642–649.
  7. Leaños-Miranda A, Navarro-Romero CS, Sillas-Pardo LJ, et al. Soluble Endoglin As a Marker for Preeclampsia, Its Severity, and the Occurrence of Adverse Outcomes. Hypertension. 2019; 74(4): 991–997.
  8. ACOG Practice Bulletin No. 202 Summary: Gestational Hypertension and Preeclampsia. Obstet Gynecol. 2019; 133(1): 211–214.
  9. Laine K, Murzakanova G, Sole KB, et al. Prevalence and risk of pre-eclampsia and gestational hypertension in twin pregnancies: a population-based register study. BMJ Open. 2019; 9(7): e029908.
  10. Bartnik P, Kosinska-Kaczynska K, Kacperczyk J, et al. Twin Chorionicity and the Risk of Hypertensive Disorders: Gestational Hypertension and Pre-eclampsia. Twin Res Hum Genet. 2016; 19(4): 377–382.
  11. Sarno L, Maruotti GM, Donadono V, et al. Risk of preeclampsia: comparison between dichorionic and monochorionic twin pregnancies. J Matern Fetal Neonatal Med. 2014; 27(10): 1080–1081.
  12. Sparks TN, Cheng YW, Phan N, et al. Does risk of preeclampsia differ by twin chorionicity? J Matern Fetal Neonatal Med. 2013; 26(13): 1273–1277.
  13. Campbell DM, Templeton A. Maternal complications of twin pregnancy. Int J Gynaecol Obstet. 2004; 84(1): 71–73.
  14. Campbell DM, MacGillivray I. Preeclampsia in twin pregnancies: incidence and outcome. Hypertens Pregnancy. 1999; 18(3): 197–207.
  15. Savvidou MD, Karanastasi E, Skentou C, et al. Twin chorionicity and pre-eclampsia. Ultrasound Obstet Gynecol. 2001; 18(3): 228–231.
  16. Leduc L, Takser L, Rinfret D. Persistance of adverse obstetric and neonatal outcomes in monochorionic twins after exclusion of disorders unique to monochorionic placentation. Am J Obstet Gynecol. 2005; 193(5): 1670–1675.
  17. Bdolah Y, Lam C, Rajakumar A, et al. Twin pregnancy and the risk of preeclampsia: bigger placenta or relative ischemia? Am J Obstet Gynecol. 2008; 198(4): 428.e1–428.e6.
  18. Faupel-Badger JM, McElrath TF, Lauria M, et al. Maternal circulating angiogenic factors in twin and singleton pregnancies. Am J Obstet Gynecol. 2015; 212(5): 636.e1–636.e8.
  19. Jeyabalan A, Powers RW, Clifton RG, et al. Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network, Eunice Kennedy Shriver National Institute of Child Health Human Development Maternal-Fetal Medicine Units Network. Soluble fms-Like tyrosine kinase 1 (sFlt1), endoglin and placental growth factor (PlGF) in preeclampsia among high risk pregnancies. PLoS One. 2010; 5(10): e13263.
  20. Sánchez O, Llurba E, Marsal G, et al. First trimester serum angiogenic/anti-angiogenic status in twin pregnancies: relationship with assisted reproduction technology. Hum Reprod. 2012; 27(2): 358–365.
  21. Boucoiran I, Thissier-Levy S, Wu Y, et al. MIROS Study Group. Risks for preeclampsia and small for gestational age: predictive values of placental growth factor, soluble fms-like tyrosine kinase-1, and inhibin A in singleton and multiple-gestation pregnancies. Am J Perinatol. 2013; 30(7): 607–612.
  22. Dröge L, Herraìz I, Zeisler H, et al. Maternal serum sFlt-1/PlGF ratio in twin pregnancies with and without pre-eclampsia in comparison with singleton pregnancies. Ultrasound Obstet Gynecol. 2015; 45(3): 286–293.
  23. Saleh L, Tahitu SIM, Danser AH, et al. The predictive value of the sFlt-1/PlGF ratio on short-term absence of preeclampsia and maternal and fetal or neonatal complications in twin pregnancies. Pregnancy Hypertens. 2018; 14: 222–227.
  24. Maynard SE, Moore Simas TA, Solitro MJ, et al. Circulating angiogenic factors in singleton vs multiple-gestation pregnancies. Am J Obstet Gynecol. 2008; 198(2): 200.e1–200.e7.
  25. Svirsky R, Levinsohn-Tavor O, Feldman N, et al. First- and second-trimester maternal serum markers of pre-eclampsia in twin pregnancy. Ultrasound Obstet Gynecol. 2016; 47(5): 560–564.
  26. Francisco C, Wright D, Benkő Z, et al. Competing-risks model in screening for pre-eclampsia in twin pregnancy according to maternal factors and biomarkers at 11-13 weeks' gestation. Ultrasound Obstet Gynecol. 2017; 50(5): 589–595.
  27. Cowans NJ, Spencer K. First trimester maternal serum placental growth factor levels in twin pregnancies. Prenat Diagn. 2013; 33(13): 1260–1263.
  28. Tsiakkas A, Cazacu R, Wright A, et al. Maternal serum placental growth factor at 12, 22, 32 and 36 weeks' gestation in screening for pre-eclampsia. Ultrasound Obstet Gynecol. 2016; 47(4): 472–477.
  29. Zeisler H, Llurba E, Chantraine F, et al. Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia. N Engl J Med. 2016; 374(1): 13–22.
  30. Rana S, Hacker MR, Modest AM, et al. Circulating angiogenic factors and risk of adverse maternal and perinatal outcomes in twin pregnancies with suspected preeclampsia. Hypertension. 2012; 60(2): 451–458.
  31. Metz TD, Allshouse AA, Euser AG, et al. Preeclampsia in high risk women is characterized by risk group-specific abnormalities in serum biomarkers. Am J Obstet Gynecol. 2014; 211(5): 512.e1–512.e6.
  32. Maymon R, Trahtenherts A, Svirsky R, et al. Developing a new algorithm for first and second trimester preeclampsia screening in twin pregnancies. Hypertens Pregnancy. 2017; 36(1): 108–115.
  33. Rana S, Powe CE, Salahuddin S, et al. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation. 2012; 125(7): 911–919.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl